Inotrem Employee Directory
Biotechnology ResearchÎle-de-france, France11-50 Employees
Inotrem is a French biotechnology company founded in 2013 that focuses on developing therapies for inflammatory and immune-related conditions by targeting the TREM-1 pathway. Operating from Paris and with a technology center in Nancy, the company pursues a personalized medicine approach to manage life-threatening inflammatory syndromes with high unmet medical need. Its lead candidate nangibotide aims to recalibrate the inflammatory response in septic shock and severe COVID-19, and it is being developed together with Roche Diagnostics through a companion diagnostic platform to identify patients most likely to benefit. The program has a defined regulatory path for septic shock, and nangibotide has earned EMA PRIME designation and Fast Track status from the FDA.